Gossamer Bio Inc. (NASDAQ: GOSS) is -51.61% lower on its value in year-to-date trading and has touched a low of $1.18 and a high of $15.19 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GOSS stock was last observed hovering at around $1.32 in the last trading session, with the day’s loss setting it -0.27% off its average median price target of $7.00 for the next 12 months. It is also 93.0% off the consensus price target high of $15.00 offered by 14 analysts, but current levels are 47.5% higher than the price target low of $2.00 for the same period.
Currently trading at $1.05, the stock is -38.78% and -49.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.82 million and changing -20.45% at the moment leaves the stock -86.71% off its SMA200. GOSS registered -87.56% loss for a year compared to 6-month loss of -92.73%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a -53.33% gain in the last 1 month and extending the period to 3 months gives it a -54.94%, and is -20.75% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.29% over the week and 12.67% over the month.
Distance from 52-week low is -11.02% and -93.09% from its 52-week high.
Gossamer Bio Inc. (GOSS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Gossamer Bio Inc. (GOSS) is a “Overweight”. 14 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Gossamer Bio Inc. is expected to release its quarterly report on 05/16/2023.The EPS is expected to grow by 12.00% this year
Gossamer Bio Inc. (GOSS) Top Institutional Holders
The shares outstanding are 91.18M, and float is at 89.93M with Short Float at 29.60%.
Gossamer Bio Inc. (GOSS) Insider Activity
A total of 4 insider transactions have happened at Gossamer Bio Inc. (GOSS) in the last six months, with sales accounting for 4 and purchases happening 0 times. The most recent transaction is an insider sale by Carter Laura, the company’s Chief Scientific Officer. SEC filings show that Carter Laura sold 4,876 shares of the company’s common stock on Oct 24 at a price of $12.07 per share for a total of $58868.0. Following the sale, the insider now owns 82292.0 shares.
Gossamer Bio Inc. disclosed in a document filed with the SEC on Oct 24 that Aranda Richard (Chief Medical Officer) sold a total of 4,757 shares of the company’s common stock. The trade occurred on Oct 24 and was made at $12.07 per share for $57431.0. Following the transaction, the insider now directly holds 0.21 million shares of the GOSS stock.
Still, SEC filings show that on Oct 24, Peterson Caryn (EVP, Regulatory Affairs) disposed off 4,757 shares at an average price of $12.07 for $57431.0. The insider now directly holds 61,415 shares of Gossamer Bio Inc. (GOSS).
Gossamer Bio Inc. (GOSS): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -12.55% down over the past 12 months and Merck & Co. Inc. (MRK) that is 36.50% higher over the same period. AbbVie Inc. (ABBV) is -0.37% down on the 1-year trading charts.